RPTX Repare Therapeutics Inc.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
RP-3500
Solid tumors
|
Phase 1/2
Phase 1/2
|
Phase 1/2 dosing of first patient announced July 29, 2020.
|
Latest News
-
View Full Article Hide Full Article
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team are scheduled to participate in three virtual investor conferences in March. Details are as follows:
Cowen 41st Annual Health Care Conference
Panel Discussion Title: Ovarian Cancer
Date: Tuesday, March 2, 2021
Time: 12:50 p.m. Eastern TimeH.C. Wainwright Annual Global Life Sciences Conference
Date: Tuesday, March 9 – Wednesday, March 10, 2021Morgan Stanley Virtual Healthcare Corporate Access Day
Date: Tuesday, March 16, 2021The prerecorded H.C. Wainwright presentation will be available on Tuesday, March 9, 2021, at 7:00 a.m. Eastern Time in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company's website for 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor and a Polθ inhibitor program. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005218/en/
-
View Full Article Hide Full Article
TORONTO, Jan. 5, 2021 /CNW/ - While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results.
77 IPOs including capital pool companies (CPCs) and SPACs were completed in 2020 on four Canadian stock exchanges, raising $5.55 billion in aggregate gross proceeds, or excluding CPCs and SPACs, 43 IPOs for $4.85 billion.
The 2020 IPO numbers represent a decrease of 29% in total number of IPOs and an increase of 116% in total amount or, excluding CPC/SPAC IPOs, a decrease of 7% in total IPO number and an increase of 605% in total amount from 2019.
Excluding CPC/SPAC IPOs, CSE continues to lead all Canadian exchanges with 25 IPOs (58%), comparing to 31 IPOs (67%) in 2019.
Mining issuers led all sectors with 23 IPOs for $324 million, accounting for 53% and 7% of the total number of Non-CPC/SPAC IPOs and total amount respectively.
4 Private Equity (PE) and 2 Venture Capital (VC) backed IPOs dominated the total amount, raising $3,395 million and $144 million respectively, or $3,539 million in aggregate, representing 64% of total IPO amount or 73% of total Non-CPC/SPAC IPO amount.
2020 IPO Breakdown by Exchanges (Non-CPC/SPAC)
- CSE – 25 IPOs for $43 million (25 IPOs for $43 million)
- TSX – 11 IPO for $4,726 million (10 IPOs for $4,460 million)
- TSX Venture Exchange – 39 IPOs for $364 million (8 IPOs for $350 million)
- NEO – 2 IPOs for $421 million (nil)
2020 Canadian IPOs League Table – Top 8 Law Firms (by # IPOs only)
All IPO Ranking (#, $total IPO value)
- Miller Thomson LLP (13, $17M)
- Blake, Cassels & Graydon LLP (11, $1,549M)
- DuMoulin Black LLP (8, $17M)
- Cassels Brock & Blackwell LLP (7, $38M)
- Harper Grey LLP (7, $10M)
- MLT Aikins LLP (7, $5M)
- Peterson McVicar LLP (7, $2M)
- Borden Ladner Gervais LLP (6, $12M)
Non-CPC/SPAC IPO Ranking (#, $total IPO value)
- Blake, Cassels & Graydon LLP (8, $861M)
- Miller Thomson LLP (7, $16M)
- Stikeman Elliott LLP (5, $2,165M)
- DuMoulin Black LLP (5, $16M)
- Harper Grey LLP (5, $10M)
- Cassels Brock & Blackwell LLP (4, $37M)
- Vantage Law Corporation (4, $6M)
- Lotz & Company (4, $2M)
2020 Canadian IPOs League Table – Top 13 Underwriters (by # IPOs Only)
All IPO Ranking (#, $total IPO value)
- Canaccord Genuity Corp. (26, $2,535M)
- Haywood Securities Inc. (24, $ 25M)
- BMO Nesbitt Burns Inc. (12, $ 4,651M)
- Scotia Capital Inc. (9, $4,349M)
- CIBC World Markets Inc. (8, $4,372M)
- Leede Jones Gable Inc. (8, $12M)
- Raymond James Ltd. (7, $4,053M)
- TD Securities Inc. (7, $4,045M)
- National Bank Financial Inc. (7, $4,039M)
- Industrial Alliance Securities Inc. (7, $1,017M)
- Mackie Research Capital Corporation (7, $9M)
- RBC Dominion Securities Inc. (6, $4,006M)
- Stifel Nicolaus Canada Inc. (6, $3,623M)
Non-CPC/SPAC IPO Ranking (#, $total IPO value)
- Canaccord Genuity Corp. (17, $1,846M)
- BMO Nesbitt Burns Inc. (12, $4,651M)
- Haywood Securities Inc. (9, $20M)
- Scotia Capital Inc. (9, $4,349M)
- CIBC World Markets Inc. (8, $4,372M)
- Raymond James Ltd. (7, $4,053M)
- TD Securities Inc. (7, $4,045M)
- National Bank Financial Inc. (7, $4,039M)
- RBC Dominion Securities Inc. (6, $4,006M)
- Stifel Nicolaus Canada Inc. (6, $3,623M)
- Leede Jones Gable Inc. (6, $12M)
- Mackie Research Capital Corporation (6, $8M)
- Desjardins Securities Inc. (5, $952M)
2020 Top Five Canadian IPOs (Canadian and foreign exchanges)
Three of top five Canadian IPOs were done on the NASDAQ Exchange. The Top Five are backed either by private equity or venture capital firms.Issuer
Backed
Close Date
$ Raised (Mil)
Exchange(s)
Valuation* ($Mil)
GFL Environmental Inc.
PE
2020-03-05
$1,425 (US)
TSX/NYSE: GFL
$6,416 (US)
Nuvei Corporation
PE
2020-09-22
$805 (US)
TSX: NVEI
$3,390 (US)
AbCellera Biologics Inc.
VC
2020-12-15
$555 (US)
NASDAQ: ABCL
$5,384 (US)
Repare Therapeutics Inc.
VC
2020-06-23
$253 (US)
NASDAD: RPTX
$700 (US)
Fusion Pharmaceuticals Inc.
VC
2020-06-30
$213 (US)
NASDAQ: FUSN
$708 (US)
Report Summary
2020 Canadian IPO Report Summary can be downloaded from financings.ca https://www.financings.ca/reports/About CPE Analytics
CPE Analytics, through financings.ca, is Canada's all public and private financing data provider. We offer comprehensive data coverage and analysis on private capital and public financings, IPOs, M&As and VC/PE fundraising. More information: https://cpeanalytics.ca
CPE Analytics is a division of CPE Media Inc., Canada's all financing news and data provider.
SOURCE CPE Media Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/05/c5740.html -
View Full Article Hide Full Article
Repare Therapeutics, Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences:
H.C. Wainwright Virtual BioConnect Conference
Date: Monday, January 11 – Thursday, January 1439th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 14
Time: 8:20 a.m. Eastern TimeThe H.C. Wainwright presentation will be pre-recorded and available on Monday, January 11, 2021, at 6:00 a.m. Eastern Time in the Investor section of the Company's website at https://ir.reparerx.com/news-and-events/events. A live webcast of the J.P. Morgan presentation will be available in the same section of the website. A replay of both webcasts will be archived for 30 days following each presentation date.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005027/en/
-
View Full Article Hide Full Article
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business & Corporate Development Kim Seth (collectively, the "Executives"), as well as certain other insiders of the Company (the "Other Insiders" and collectively with the Executives, the "Participants"), have established Automatic Securities Disposition Plans ("ASDPs") in accordance with applicable United States and Canadian securities legislation, including the recommended practices set forth in the recently issued Canadian Securities Administrators' Staff Notice 55-317("Staff Notice 55-317") and the Company's internal policies.
While Repare is listed on the Nasdaq Global Select Market, it is also considered a reporting issuer under the Securities Act (Québec) and is therefore announcing the establishment of the ASDPs in furtherance of the recently published guidance provided by the Canadian Securities Administrators in Staff Notice 55-317.
Under U.S. and Canadian securities laws and the Company's trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company. The ASDPs address this issue by permitting trades to be made in accordance with pre-arranged instructions given when Participants are not in possession of any material undisclosed information.
Up to 211,931 common shares of Repare may be sold under the ASDPs implemented by the Executives in the aggregate, and up to 227,341 common shares of Repare may be sold under the ASDPs implemented by the Other Insiders. The ASDPs are designed to allow for an orderly disposition of each of the Participants' shares in Repare at prevailing market prices over the course of the 12 to 24 months that the ASDPs are expected to be in place. Sales of the common shares under the ASDPs will only commence after the Company has filed its next annual financial statements for the fiscal year ended December 31, 2020, in accordance with the recent recommended practices set forth in Staff Notice 55-317.
Each Participant has provided for clear trading parameters and other instructions in writing to the independent dealers administering the ASDPs, specifying the number of securities to be sold and setting out minimum trade prices, which in most cases exceed the current trading price of the Company's common shares, and the dates or frequencies of sales. The ASDPs prohibit the dealer administering the ASDPs from consulting with the Participants regarding any sales under the ASDPs and prohibit the Participants from disclosing to the dealer any information concerning the Company that might influence the execution of the ASDPs.
The ASDPs contain meaningful restrictions on the ability of the Participants to amend, suspend or terminate the ASDPs that have the effect of ensuring that the Participants cannot benefit from material non-public information..
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201231005240/en/
-
View Full Article Hide Full Article
Repare Therapeutics, Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Repare's addition to the NBI will become effective prior to market open on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.
For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics, Inc.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery of potential product candidates using SNIPRx® platform; and the clinical development of the Company's pipeline and its research and development programs, including the anticipated timing of its clinical trials of RP-3500 and RP-6306; and the development of preclinical assets pursuant to the Company's collaboration with Bristol Myers Squibb. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company's business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission (the "SEC") on November 12, 2020, and its subsequent filings with the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005830/en/